Jay Stern, MD
Internal Medicine · Hyattsville, MDNPI 1598952160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2024 at $825 and has fallen 64.1% since, to $296 in 2025.
Across 88 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$440
- AstraZeneca$253
- Lilly USA, LLC$169
- Bayer$167
- Johnson & Johnson$108
- Boehringer Ingelheim$94
- plus $501 from 15 others
What the payments were for
- Food & beverage$1,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $440 |
| AstraZeneca | 11 | $253 |
| Lilly USA, LLC | 9 | $169 |
| Bayer | 12 | $167 |
| Johnson & Johnson | 3 | $108 |
| Boehringer Ingelheim | 5 | $94 |
| Pfizer | 4 | $72 |
| Exact Sciences | 2 | $66 |
| Merck | 4 | $60 |
| Amgen | 2 | $41 |
| Phadia US Inc. | 2 | $37 |
| Cranial Technologies, Inc | 3 | $37 |
| Seqirus USA Inc | 2 | $33 |
| Biogen | 1 | $28 |
| Astellas Pharma US Inc | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
How this compares
$1,733 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 125 | $1,853 |
| Amlodipine Besylate | 183 | $1,448 |
| Rosuvastatin Calcium | 39 | $995 |
| Losartan Potassium | 78 | $900 |
| Metoprolol Succinate | 43 | $783 |
| Simvastatin | 55 | $565 |
| Metformin Hcl | 57 | $435 |
| Pioglitazone Hcl | 12 | $377 |
| Lisinopril | 50 | $357 |
| Alendronate Sodium | 31 | $259 |
| Levothyroxine Sodium | 32 | $209 |
| Carvedilol | 11 | $151 |
| Hydrochlorothiazide | 46 | $151 |
| Montelukast Sodium | 11 | $91 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Hyattsville
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.